Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRAT | P43155 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CPT2 | P23786 | 2/20 | 0.42 |
| ▸ | CPT1A | P50416 | 2/20 | 0.42 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687568 | 1.00 | CRAT (0.50) | CRATKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL13409974 | 0.90 | KMT2A (0.51) | KMT2AMEN1HTTSMN1; SMN2HDAC1 | |
| SCHEMBL10414822 | 0.90 | CRAT (0.58) | CRATCTRB1CTSGHPGDCPT2 | |
| SCHEMBL10414824 | 0.90 | CRAT (0.58) | CRATCTRB1CTSGHPGDCPT2 | |
| SCHEMBL3686493 | 0.89 | CRAT (0.47) | CRATKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL3686496 | 0.89 | CRAT (0.47) | CRATKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL3694531 | 0.85 | CRAT (0.45) | CRATHTTSMN1; SMN2HPGDCPT2 | |
| SCHEMBL3694527 | 0.85 | CRAT (0.45) | CRATHTTSMN1; SMN2HPGDCPT2 | |
| SCHEMBL3679669 | 0.84 | CPT2 (0.57) | CPT2CPT1ACPT1B | |
| SCHEMBL3679668 | 0.84 | CPT2 (0.57) | CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | claimed |
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CRAT 5/4885KMT2A 662/4885MEN1 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.